Radiotherapy remains the treatment of first choice for high-risk low-grade glioma

(European Organisation for Research and Treatment of Cancer) In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news